Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 10;17(5):1436-1439.
doi: 10.5114/aoms/140544. eCollection 2021.

Mechanism of tangshen formula in treating diabetic nephropathy revealed by network pharmacology approach

Na Quan  1   2 , Junfu Guo  2
Affiliations

Mechanism of tangshen formula in treating diabetic nephropathy revealed by network pharmacology approach

Na Quan et al. Arch Med Sci. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The pharmacological network of TSF. The purple triangle indicates herbal medicine, the yellow quadrangle indicates the compound, the red dot indicates upregulated targets, the green diamond indicates downregulated targets, and the blue hexagon indicates the KEGG pathway
See this image and copyright information in PMC

References

    1. Narres M, Claessen H, Droste S, et al. The incidence of end-stage renal disease in the diabetic (compared to the non-diabetic) population: a systematic review. PLoS One. 2016;11:e0147329. - PMC - PubMed
    1. Stephens JW, Brown KE, Min T. Chronic kidney disease in type 2 diabetes: implications for managing glycaemic control, cardiovascular and renal risk. Diabetes Obesity Metabol. 2020;22(Suppl 1):32–45. - PubMed
    1. Yi W, OuYang Q. Adiponectin improves diabetic nephropathy by inhibiting necrotic apoptosis. Arch Med Sci. 2019;15:1321–8. - PMC - PubMed
    1. Ekiz-Bilir B, Bilir B, Aydın M, Soysal-Atile N. Evaluation of endocan and endoglin levels in chronic kidney disease due to diabetes mellitus. Arch Med Sci. 2019;15:86–91. - PMC - PubMed
    1. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9. - PubMed